WBRT yields median survival of 3.6 months in Nigerian brain metastases patients
Brain radiation extends life by 3.6 months in Nigerian patients
This systematic review of 142 patients with brain metastases in Nigeria found that whole brain radiotherapy (WBRT) was associated with a med…
Whole brain radiotherapy gave Nigerian breast cancer patients with brain metastases a median survival of 3.6 months. A new review reveals th…
Immunomodulatory interventions targeting the ovarian immune microenvironment may address functional decline in aging and POI
Immune system changes drive ovarian aging and fertility decline
This systematic review examines how dysregulation of the local ovarian immune microenvironment, including Treg/Th17 balance and macrophage p…
New research identifies how the immune environment in the ovaries drives age-related decline and may offer a path for new treatments.
Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS
Different Medications Show Different Benefits for Myelodysplastic Syndromes
This systematic review and network meta-analysis of 20 trials involving 2,877 participants evaluated pharmacological treatments for lower-ri…
New research shows different medications offer varying benefits for patients with lower-risk myelodysplastic syndromes based on specific hea…
Intracranial immunotherapy delivery does not improve survival for pediatric high-grade glioma compared to systemic administration
Intracranial Delivery Shows Higher Neurotoxicity Risk in Pediatric Brain Tumors
This meta-analysis of 22 studies evaluated intracranial versus systemic immunotherapy delivery in pediatric patients with high-grade and dif…
New analysis shows that while delivery methods do not change survival for pediatric brain tumors, some routes carry a higher risk of severe …
PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
Different PD-1 Inhibitors Show Varying Results for Nasopharyngeal Cancer
This systematic review and meta-analysis of 1,459 patients with recurrent or metastatic nasopharyngeal carcinoma found a pooled objective re…
A review of 1,459 patients shows that different PD-1 inhibitors combined with chemotherapy offer varying survival and response rates for nas…
Combination strategies using DNA damage response inhibitors aim to overcome resistance in pancreatic cancer
New combination strategies aim to treat pancreatic cancer more effectively
This systematic review evaluates DNA damage response (DDR) inhibitors, including monotherapy and combination regimens, for pancreatic cancer…
Combining different drugs could help overcome treatment resistance and reach more patients with pancreatic cancer.
Radiomics-based machine learning achieves high AUROC for preoperative risk stratification in bladder cancer
Machine Learning May Help Identify Risks in Bladder Cancer
This systematic review and meta-analysis of 57 studies involving 11,933 participants evaluated radiomics-based machine learning for preopera…
New analysis shows machine learning can help identify muscle invasion and tumor grades in patients with bladder cancer using imaging data.
Specific clinical and radiological features may identify risk for leptomeningeal dissemination in oligodendroglioma
Risk Markers Linked to Spread of Oligodendroglioma in Spinal Fluid
This scoping review of 15 studies identifies several indicators associated with leptomeningeal dissemination (LMD) in patients with oligoden…
Identifying specific markers like high Ki-67 levels and ventricular involvement may help doctors track the spread of certain brain tumors.
HOX gene dysregulation influences cellular processes but currently lacks utility as reliable HNSCC biomarkers
HOX genes play complex roles in head and neck cancer
This mini-review examines the role of HOX genes in head and neck squamous cell carcinoma (HNSCC). The authors conclude that while these gene…
New research highlights how HOX genes drive tumor growth and survival in head and neck cancers, though their use as clinical tools is still …
FDA Approves Alecensa (alectinib) for Adjuvant Treatment of ALK-Positive NSCLC
FDA approves Alecensa for early lung cancer after surgery to reduce recurrence risk.
The FDA approved Alecensa (alectinib) for adjuvant treatment of ALK-positive NSCLC after tumor resection in patients with tumors ≥4 cm or no…
The FDA approved Alecensa (alectinib) for patients with ALK-positive non-small cell lung cancer after surgery, if the tumor was large or had…
FDA Approves Yervoy (ipilimumab) for Multiple Indications Including Melanoma and Lung Cancer
FDA approves Yervoy for several advanced cancers including melanoma and lung cancer.
The FDA approved Yervoy (ipilimumab) for unresectable or metastatic melanoma, adjuvant melanoma, advanced renal cell carcinoma, MSI-H/dMMR c…
The FDA has approved Yervoy (ipilimumab) for many advanced cancers, including melanoma, lung, kidney, and colon cancers. It is used alone or…
Sacubitril/Valsartan preserves left ventricular systolic function and attenuates GLS deterioration during chemotherapy
Sacubitril and Valsartan May Protect Heart Function During Chemotherapy
This meta-analysis of randomized controlled trials evaluates sacubitril/valsartan for patients undergoing chemotherapy to manage chemotherap…
A new review suggests the medication sacubitril/valsartan may help preserve heart muscle function for patients undergoing chemotherapy.